Doxorubicin-loaded highly porous large PLGA microparticles as a sustained- release inhalation system for the treatment of metastatic lung cancer.

Doxorubicin-loaded highly porous large PLGA microparticles (Dox PLGA MPs) were prepared using a w/o/w double emulsification method using ammonium bicarbonate effervescent salt. The prepared Dox PLGA MPs were characterized by particle size analysis, scanning electron microscopy, and confocal microscopy. In vitro cytotoxicity to B16F10 melanoma cells and lung deposition in C57BL/6 mice were examined, and finally the anti-tumor efficacy of pulmonary administered Dox PLGA MPs was evaluated in a mouse model of B16F10 melanoma metastasis. Results showed that Dox PLGA MPs were highly porous, had high encapsulation efficiency, and good aerosolization characteristics. Doxorubicin was gradually released from Dox PLGA MPs over 2 weeks, and after pulmonary administration, Dox PLGA MPs were deposited in lungs and remained in situ for up to 14 days. Furthermore, exposure to Dox PLGA MPs killed B16F10 cells in vitro within 24 h. In particular, tumors in B16F10-implanted mice treated with Dox PLGA MPs were remarkably smaller in terms of mass and number than those in non-treated B16F10-implanted mice. We believe that doxorubicin-loaded highly porous large PLGA microparticles have great potential as a long-term inhalation agent for the treatment of lung cancer.

[1]  H. Burris,et al.  Shortcomings of current therapies for non-small-cell lung cancer: unmet medical needs , 2009, Oncogene.

[2]  Kwideok Park,et al.  Fabrication of covered porous PLGA microspheres using hydrogen peroxide for controlled drug delivery and regenerative medicine. , 2009, Journal of controlled release : official journal of the Controlled Release Society.

[3]  Xiaoyuan Chen,et al.  PEGylated TNF-related apoptosis-inducing ligand (TRAIL) for effective tumor combination therapy. , 2011, Biomaterials.

[4]  Xun Hu,et al.  Schisandrin B enhances doxorubicin-induced apoptosis of cancer cells but not normal cells. , 2006, Biochemical pharmacology.

[5]  H. Chung,et al.  Biodegradable polymeric microspheres with "open/closed" pores for sustained release of human growth hormone. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[6]  R. Langer,et al.  Recent advances in pulmonary drug delivery using large, porous inhaled particles. , 1998, Journal of applied physiology.

[7]  R. Kiss,et al.  In vivo assessment of temozolomide local delivery for lung cancer inhalation therapy. , 2010, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[8]  N Lotan,et al.  Large porous particles for pulmonary drug delivery. , 1997, Science.

[9]  D. Johnson,et al.  Treatment strategies for metastatic non small-cell lung cancer. , 1999, Clinical lung cancer.

[10]  S. Kong,et al.  Oncogene AF1q enhances doxorubicin-induced apoptosis through BAD-mediated mitochondrial apoptotic pathway , 2008, Molecular Cancer Therapeutics.

[11]  F. Veronese,et al.  PEG-doxorubicin conjugates: influence of polymer structure on drug release, in vitro cytotoxicity, biodistribution, and antitumor activity. , 2005, Bioconjugate chemistry.

[12]  M. Shive,et al.  Biodegradation and biocompatibility of PLA and PLGA microspheres , 1997 .

[13]  Y. Yeo,et al.  Development of highly porous large PLGA microparticles for pulmonary drug delivery. , 2009, Biomaterials.

[14]  L. Vassilev,et al.  p21 does not protect cancer cells from apoptosis induced by nongenotoxic p53 activation , 2011, Oncogene.

[15]  Eun Seong Lee,et al.  Albumin-Coated Porous Hollow Poly(Lactic-co-Glycolic Acid) Microparticles Bound with Palmityl-Acylated Exendin-4 as a Long-Acting Inhalation Delivery System for the Treatment of Diabetes , 2011, Pharmaceutical Research.

[16]  Peter R. Byron,et al.  Inhaling medicines: delivering drugs to the body through the lungs , 2007, Nature Reviews Drug Discovery.

[17]  R. Löbenberg,et al.  Inhalable nanoparticles, a non-invasive approach to treat lung cancer in a mouse model. , 2011, Journal of controlled release : official journal of the Controlled Release Society.

[18]  T. Park,et al.  Gas foamed open porous biodegradable polymeric microspheres. , 2006, Biomaterials.

[19]  Ching-Li Tseng,et al.  The use of biotinylated-EGF-modified gelatin nanoparticle carrier to enhance cisplatin accumulation in cancerous lungs via inhalation. , 2009, Biomaterials.

[20]  R. Langer,et al.  Formulation and Physical Characterization of Large Porous Particles for Inhalation , 1999, Pharmaceutical Research.

[21]  G. Baker,et al.  Inhalation toxicity and lung toxicokinetics of C60 fullerene nanoparticles and microparticles. , 2008, Toxicological sciences : an official journal of the Society of Toxicology.

[22]  Ming-Jium Shieh,et al.  Targeting efficiency and biodistribution of biotinylated-EGF-conjugated gelatin nanoparticles administered via aerosol delivery in nude mice with lung cancer. , 2008, Biomaterials.

[23]  Anderson,et al.  Biodegradation and biocompatibility of PLA and PLGA microspheres. , 1997, Advanced drug delivery reviews.

[24]  Eun Seong Lee,et al.  Doxorubicin-loaded human serum albumin nanoparticles surface-modified with TNF-related apoptosis-inducing ligand and transferrin for targeting multiple tumor types. , 2012, Biomaterials.

[25]  Lisa M. Schwartz,et al.  Are increasing 5-year survival rates evidence of success against cancer? , 2000, JAMA.

[26]  M. L. La Rotonda,et al.  Cyclodextrins in the production of large porous particles: development of dry powders for the sustained release of insulin to the lungs. , 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[27]  D. Jaroszewski,et al.  Video-assisted thoracic surgery (VATS) as a safe alternative for the resection of pulmonary metastases: a retrospective cohort study , 2009, Journal of cardiothoracic surgery.

[28]  He-long Zhang,et al.  Activity of a new vascular targeting agent, ZD6126, in pulmonary metastases by human lung adenocarcinoma in nude mice. , 2002, Cancer research.

[29]  Min Jung Kwon,et al.  Long acting porous microparticle for pulmonary protein delivery. , 2007, International journal of pharmaceutics.

[30]  Gediminas Mainelis,et al.  Inhibition of lung tumor growth by complex pulmonary delivery of drugs with oligonucleotides as suppressors of cellular resistance , 2010, Proceedings of the National Academy of Sciences.

[31]  Eun Seong Lee,et al.  Highly porous large poly(lactic-co-glycolic acid) microspheres adsorbed with palmityl-acylated exendin-4 as a long-acting inhalation system for treating diabetes. , 2011, Biomaterials.